A review shows that ATG10 has been identified as a potential prognostic marker and therapeutic target for cancer patients based on real-world studies
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Autophagy-related gene 10 (ATG10) promotes cancer growth and metastasis. Inhibiting ATG10 may offer a new therapeutic strategy for various cancers, as its overexpression correlates with poor prognosis.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Autophagy-related genes (ATGs) are critical in cancer development and progression.
- ATG10, an ATG family member, is frequently overexpressed in multiple cancers, correlating with poor prognosis and advanced disease.
- ATG10 influences tumorigenesis by affecting epithelial-mesenchymal transition and cell cycle regulation.
Purpose Of The Study
- To review the functional and clinical significance of ATG10 in various cancers.
- To highlight ATG10's potential as a diagnostic biomarker and therapeutic target.
Main Methods
- Literature review of studies on ATG10 in cancer.
- Analysis of ATG10's role in cancer progression, metastasis, and therapeutic resistance.
- Identification of factors that modulate ATG10 activity.
Main Results
- ATG10 overexpression is linked to poor outcomes in endometrial, liver, leukemia, nasopharyngeal, gastric, and colorectal cancers.
- ATG10 promotes cancer progression by modulating epithelial-mesenchymal transition and cell cycle regulators (cyclin B1, CDK1, CDK2).
- ATG10 activity is inhibited by DDX10, PTBP1, sodium orthovanadate, podofilox, SIRT6, FAT1, SOX2, and specific microRNAs.
Conclusions
- ATG10 is a significant driver of cancer progression and metastasis across multiple malignancies.
- Targeting ATG10 presents a promising therapeutic avenue for cancer treatment.
- Further research into ATG10's regulatory mechanisms and inhibitors is warranted for clinical application.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...